Search 

AEBi was established in the year 2000, and has been managed since then based on the idea that the ability to manipulate and design peptides has vastly superior advantages to many, if not any, existing and trajectory technologies of drug development. This idea is valid today as well.The basic idea is that we do not require a natural lead or a sequence (usually coming from the academia or other research) which are either not strong enough or not specific enough and difficult to manipulate in order to create a drug.
An artificial high complexity pool, representing a broad spectrum of  possibilities, manipulated by our technology, will provide the best possible solution. Such a  solution  will not be hindered or blocked by natural interactions and will be very specific to the problem.
AEBi, a development-stage biopharmaceutical company engaged in discovery and development of therapeutic peptides, has developed a combinatorial biology screening platform technology (IP protected).
The major advantage is that it can be used not only to find binders to known targets, but to select the best functional molecules among them. AEBi's platform is very flexible, exploiting combinatorial biology to discover new and better lead compounds to disease targets.

Our Breakthrough SoAP Platform:
-------------------------------------------------
Our platform provides functional leads to very difficult targets (functional leads - agonist, antagonist, inhibitor, etc.), not merely those that best bind with the target.

Moreover, it allows us to develop drugs to many illnesses, among them CANCER and COVID19, and is expected to transform the drug discovery R&D phase by significantly reducing the attrition rate of new drug candidates.
This Breakthrough technology generates very specific lead compounds with greater functionality and improved pharmacological properties. Such lead Compounds will allow more effective drugs and fewer side effects. The need for such technology is acute and pressing for many reasons. The sole external requirement in the screening process is a Defined Target (usually an illness-related protein).

MuTaTo: our Multiple Targeted Comprehensive Cancer Therapy
-------------------------------------------------------------------------------------
This new cancer treatment is a personalized medicine concept, that can be also turned into a "shelf product". The main principal of it is using multiple targeting peptides connected together with a toxin. The main advantage of it is that it would lower the probability of the targeted cancer cells to develop drug-resistance due to mutations they possess, and at the same time would lower adverse effects due to avidity effect. Each cancer patient would receive a specific drug perfectly suited to his/her cancer, based on the expression profile of receptors on the outer membrane of their cancer cells. This therapy's construct production is easy and rapid. Therefore, the production cost would not be as expensive as with other biological drugs, or other sophisticated cancer treatments.
MuTaTo our Multiple Targeted Safe Cancer Therapy is DIFFERENT and UNIQUE because:
----------------------------------------------------------------
1- It is EFFECTIVE on almost all types of CANCERS because we will develop a MuTaTo molecule for every type of cancers.
2- it is SAFE on healthy cells and DOESN'T cause any suffering to patients.
3- unlike other cancer therapies that attack cancer from only one or 2 targets at most , MuTaTo is DIFFERENT because it attacks cancer from at least 3 targets so that cancer DOESN'T metastasize nor develop drug resistance.
4- MuTaTo can treat almost all types of cancers even rare one and is effective on all cancer stages even terminal ones.
5- our MuTaTo is so versatile it can be:
a) used as personalized Cancer therapy where each cancer patient would receive a specific drug perfectly suited to his/her cancer, based on the expression profile of receptors on the outer membrane of their cancer cells.
b) or it can be mass produced as a "shelf Product - Oncolytic Drug" to treat different cancers with different indications, so we will have not just one MuTaTo Drug, but a COMPLETE FAMILY OF MuTaTo DRUGS, to treat almost all types and indications of Cancers , from all stages, even rare and Terminal cancers.

Our MUTATO Cancer treatment is PATENTED,
https://patents.google.com/patent/WO2018061004A1/en?inventor=Ilan+morad&oq=Ilan+morad

Our PLATFORM is patented
https://patents.google.com/patent/WO2007010525A3/en?inventor=Ilan+morad&oq=Ilan+morad

Our concept is peer approved and we have proof of concept, and published in the prestigious Cancer Therapy Magazine
https://m.scirp.org/papers/98400

-Chinese Journals have written about our concept including MyBioGate
https://mp.weixin.qq.com/s/NYjbJDgdBOtxsAztKr7wMw
独家回访 | 一年内彻底治愈癌症,炒作还是事实？
徐子宜 Ginger 美柏企业服务
here is one article about us in another journal:
https://www.myzaker.com/article/5f88ec9f32ce40ea2900000a

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.

Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. The technology discerns key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better patient outcomes. Application areas include blood cancers, solid tumors, and genome editing validation.

Researchers at Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center (MDACC), and the University of California at San Francisco (UCSF) have leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in a variety of cancers, identifying minimal residual disease (MRD), and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Agios to enable more efficient clinical trials.

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).

央企,从事药品研发,生产,销售,产品超过300个,2019年营业收入将近100亿元,共有400人的研发团队,全国分布19个生产基地,销售网络遍布全国各省,销售团队超过2500人。希望寻找高壁垒仿制药,高端技术平台,505b2,创新化药,生物药&生物类似物的合作机会,合作方式灵活。

Baiyu , founded in 2005, is a pharmaceutical enterprise engaged in developing, manufacturing and distributing of high-quality pharmaceutical products and APIs. With about 1000 employees, Baiyu now has 6 subsidiaries including Golden Ginkgo Pharmaceutical Co., Ltd., Ginkgolide Pharmaceuticals Co., Ltd., Sunshine Ginkgo Agriculture Co.Ltd., Sichuan Yu Jian Pharmaceutical Co., Ltd. and Ginkgo Yukang Informatics Co.,Ltd., Ginkgo Yuda Pharmaceutical Co.,Ltd., et al.

Currently,we have 8 finished pharmaceutical products and 2 APIs on the market. Based on Quality-by-Design concept, our manufacturing sites strictly comply with cGMP and EU GMP. Ginkgolide injection, Enoxaparin sodium injection, Lansoprazole for injection are our main products.

Baiyu is growing fastly and has been awarded“National High-tech Enterprise”,“Sichuan Famous Brand”and“Enterprises with the most investment value in Chinese pharmaceutical industry”in 3 consecutive years.

The culture of kindness, Taiji and phoenix leads the way we behave and our vision is to constantly benefiting mankind to enjoy life-long well-being.